What Is CCRAS — and Why Their Research Matters for Every Ayurveda User in India

The 60-second version

CCRAS — the Central Council for Research in Ayurvedic Sciences — is an autonomous body of the Government of India under the Ministry of AYUSH. It was established in 1978 and operates a network of 30+ research institutes, centres, and units across India.

It runs clinical trials on Ayurvedic formulations, conducts drug-standardisation work, publishes pharmacopoeial monographs, and funds tribal-health programmes. Its trial results are deposited on CTRI (the Clinical Trials Registry of India) and indexed on PubMed when published in peer-reviewed journals.

If you have ever wondered who is actually doing systematic clinical research on classical Ayurvedic formulations rather than marketing them — this is largely it.

Why most Indian Ayurveda consumers have never heard of CCRAS

Quick observation that explains a lot. CCRAS publishes its work primarily in academic journals, attends conferences, and disseminates findings through technical reports and policy briefs. The communication infrastructure that translates this work into language a consumer can use is essentially nonexistent.

Compare this to how Western nutrition research reaches the public. The NIH funds clinical research that gets published in JAMA, NEJM, BMJ. That research gets covered by The New York Times, The Atlantic, science journalism outlets, and downstream consumer-facing health publications. By the time a consumer reads "study finds X," there is a pipeline that has translated the underlying paper at multiple levels.

The Indian Ayurveda research-to-consumer pipeline is much shorter and weaker. CCRAS publishes a paper. A few specialty journalists pick it up. The general consumer never hears about it. Meanwhile, the wellness-supplement marketing machine continues to make claims that are neither informed by nor accountable to the underlying research.

This is the gap HerbVerdict was built to fill — at least at the consumer-translation layer. CCRAS does the research. We do the translation. Neither alone is enough.

A plain-English org chart

What CCRAS has actually published

This is the part most readers find surprising. CCRAS-affiliated researchers have run trials on a meaningful slice of the herbs you read about on this site.

How to find CCRAS research yourself

Most of CCRAS's value to a reader of HerbVerdict is the ability to search their work directly when you want to verify something a brand has claimed.

Four CCRAS trials worth knowing — in plain English

Let me walk through four published CCRAS-affiliated trials with enough detail that you can decide whether they are worth tracking.

These are illustrative — the full CCRAS publication list runs to hundreds of papers. The point is that this is real, indexed research, not a black box.

How CCRAS findings compare to industry-funded findings on the same herbs

This is the test that should matter most to a careful reader: when CCRAS and industry-funded researchers study the same herb, do they reach similar conclusions?

For ashwagandha, the answer is broadly yes on the cortisol-reduction outcome — both bodies of literature support a measurable cortisol-lowering effect. CCRAS-affiliated work has been less focused on the testosterone and VO₂max claims that dominate the industry-funded ashwagandha trial base.

For triphala, CCRAS work has emphasised the digestive and antioxidant outcomes, which broadly aligns with the smaller-scale industry-funded research showing similar effects.

For Boswellia, CCRAS-affiliated work has supported the osteoarthritis findings that branded-extract manufacturers (Laila Nutra, Sabinsa, PL Thomas) have been publishing. The convergence here is meaningful — different funding streams reaching similar conclusions makes the underlying evidence more robust.

This is the use case for CCRAS data: it is a triangulation tool. When government-funded and industry-funded research point the same way, the consumer should weight that more heavily than either alone.

Why CCRAS-funded data is not the same as industry-funded data

This is the editorial point I want readers to take away.

When a supplement brand funds a trial of its own product, the result is biased toward "publish if positive, file in a drawer if negative." That bias is well-documented across every category of clinical research, not just Ayurveda.

When a government body with a research mandate funds a trial, the publication bias is structurally different. Negative results are still embarrassing, but there is no commercial pressure to bury them. Multi-centre design is more common. Conflicts of interest are reported.

What an indexed CCRAS publication actually looks like — a reader's anatomy

For readers who have never opened a CCRAS-published clinical paper, the structure is conventional. Title, authors with CCRAS affiliations, abstract, introduction, methods, results, discussion, references. Indexed in PubMed when the journal is PubMed-indexed (most major Indian Ayurveda journals are; JRAS itself has been working on indexing improvements).

Two things to look for when reading one:

First, the trial registration on CTRI. Every interventional CCRAS trial should have a CTRI number — it tells you the trial was registered prospectively, before results were known, which is the standard guard against selective reporting. If a paper doesn't cite a CTRI registration, treat it as a flag.

Second, the conflict-of-interest and funding statements. CCRAS-funded trials disclose government funding; industry-collaborative trials should disclose any commercial sponsors. The honest journals print this; the less rigorous ones sometimes don't.

Reading these declarations is the single highest-value habit a reader of clinical Ayurveda research can develop, and almost nobody who is not a researcher actually does it.

Where CCRAS still falls short — the honest part

I'm not going to write an institutional puff piece. There are limitations.

Many CCRAS trials are single-centre or small. Methodological quality is uneven across the network. Long-term follow-up is rare. The in-house journal JRAS is not as widely indexed or as scrutinised as international peer-reviewed journals. And open-data norms around trial protocols and de-identified datasets are weaker than in the global clinical-research community.

This is not a reason to ignore the work. It is a reason to read it the way you would read any clinical literature — critically, with attention to design and limitations.

How CCRAS-affiliated researchers actually work — a brief tour

For readers interested in the institutional side of Ayurveda research, this section explains what a CCRAS-affiliated researcher's day actually looks like and how that shapes the work they produce.

CCRAS operates 30+ institutes and centres across India, including dedicated research institutes for specific specialty areas — National Research Institute of Panchakarma in Cheruthuruthy, National Ayurveda Research Institute for Panchakarma, the Regional Ayurveda Research Institute for Drug Development, and others. Researchers are typically Ayurveda-trained clinicians with PhD-level research training, often holding faculty positions at affiliated Ayurveda colleges.

Their funding pipeline is largely budgetary — grant cycles tied to government fiscal years rather than industry-driven research timelines. This produces longer planning windows but also slower iteration. A CCRAS trial conceived in 2023 may not publish results until 2027.

Trial protocols are reviewed by the Council's research advisory committees and registered on CTRI before patient recruitment begins. Ethics review is conducted at the institutional level. The infrastructure is real and procedural — closer in process to NIH-funded trials in the US than to the looser commercial-research environment that produces most consumer-supplement claims.

What this means for readers: CCRAS publications are slower to land but generally hold up to procedural scrutiny better than the average industry-funded supplement trial. They are also harder to find on PubMed when the publishing journal is not well-indexed, which is a structural problem for consumer-facing research literacy.

Three CCRAS resources every Ayurveda consumer should know about

This is the practical takeaway from reading this article.

A reader who follows just these three resources over a year will see more genuine new clinical evidence on Ayurvedic herbs than ten thousand wellness Instagram posts combined.

What this article is — and what it is not

This is institutional explainer journalism, not advocacy. CCRAS does important work and also has structural limitations. The right reader posture is "track what they publish, weigh it against international evidence, treat both as inputs to your own evaluation."

I am not arguing that CCRAS-funded research is automatically more trustworthy than industry-funded research. I am arguing that consumers should know it exists, know how to find it, and know how to read it alongside other clinical literature. That is the basic literacy missing from most Indian Ayurveda discourse, and it is what HerbVerdict is here to provide.

What I will do with CCRAS research at HerbVerdict

Every herb scorecard I publish on this site will include CCRAS-published trials when they exist for that herb, treated on the same evidentiary footing as any other peer-reviewed RCT. Where CCRAS results disagree with industry-funded results, I will name the disagreement directly rather than averaging it away.

If you find a CCRAS trial that should be in one of our scorecards but isn't, write to me at the address on the methodology page.

How to use CCRAS information in your own product evaluation

Practical takeaway for readers who got this far. When you are evaluating an Ayurvedic supplement claim, here is how to fold CCRAS-relevant information into your decision.

Step one — search PubMed for the herb name plus "CCRAS" or affiliations like "Central Council." If indexed CCRAS-affiliated trials exist for that herb, read at least one. Pay attention to the trial registration on CTRI, the funding declaration, and the limitations section.

Step two — check if the herb has a monograph in the Ayurvedic Pharmacopoeia of India. The API monograph defines official identity, purity, and assay standards. A brand that explicitly meets API standards is making a regulatory claim you can verify; a brand that does not reference the API may still be reasonable but is offering you less verification.

Step three — compare CCRAS findings to industry-funded findings on the same herb. Convergence is reassuring; divergence is informative. If CCRAS-funded trials show smaller effects than industry-funded ones, that gap is itself a data point for how much weight to give the manufacturer's marketing claims.

Step four — look up whether the brand you're considering has any disclosed connection to CCRAS-affiliated researchers or institutions. Some Indian Ayurvedic companies have collaborated with CCRAS on specific product validation studies. That collaboration is a positive signal.

This is more work than most consumers will do. Most consumers do not need to do it. The point is that the option exists, the resources are public, and the information is real.

Frequently asked questions

References

1. Central Council for Research in Ayurvedic Sciences. Official website. ccras.nic.in
2. National AYUSH Mission. CCRAS overview. namayush.gov.in
3. Press Information Bureau. CCRAS Launches PRAGATI-2024. 2024. pib.gov.in
4. Journal of Research in Ayurvedic Sciences (JRAS). CCRAS in-house journal. JaypeeDigital
5. Clinical Trials Registry of India (CTRI). ctri.nic.in

Related reads on HerbVerdict